mercredi 14 septembre 2016

Big pharma approach to drug R&D challenged by UN panel

Ebola trial

Report's authors call for a de-linkage of R&D costs and drug prices — at least in areas where the system is failing, such as tropical diseases and the hunt for new antibiotics against "superbug" resistant bacteria.



0 comments:

Enregistrer un commentaire